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Abstract
Deficiency of serum levels of 25-hydroxyvitamin D3 has been correlated with increased risk of infectious diseases such as
tuberculosis and influenza. A plausible reason for this association is that expression of genes encoding important
antimicrobial proteins depends on concentrations of 1,25-dihydroxyvitamin D3 produced by activated immune cells at sites
of infection, and that synthesis of 1,25-dihydroxyvitamin D3 is dependent on the availability of 25-hydroxyvitamin D3. Thus,
increasing the availability of 25(OH)D3 for immune cell synthesis of 1,25-dihydroxyvitamin D3 at sites of infection has been
hypothesized to aid in clearance of the infection. This report details the treatment of an acute intramammary infection with
infusion of 25-hydroxyvitamin D3 to the site of infection. Ten lactating cows were infected with in one quarter of their
mammary glands. Half of the animals were treated intramammary with 25-hydroxyvitamin D3. The 25-hydroxyvitamin D3
treated animal showed significantly lower bacterial counts in milk and showed reduced symptomatic affects of the mastitis.
It is significant that treatment with 25-hydroxyvitamin D3 reduced the severity of an acute bacterial infection. This finding
suggested a significant non-antibiotic complimentary role for 25-hydroxyvitamin D3 in the treatment of infections in
compartments naturally low in 25-hydroxyvitamin D3 such as the mammary gland and by extension, possibly upper
respiratory tract infections.
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Introduction
The relationship between vitamin D status and the ability of that
animal’s immune system to effectively prevent disease is a topic of
much research in both human and veterinary medicine [1–5].
Vitamin D, following its conversion to its active form 1, 25-
dihydroxyvitamin D3 (1,25(OH)2D3), the active form of vitamin D,
is a primary regulator of calcium and skeletal homeostasis [1].
However, additional functions in the immune system became
evident in the early 1980s when it was found that 1,25(OH)2D3 was
produced by monocytes in diseased tissue, the vitamin D receptor
was identified in immune tissues and some immune functions were
shown to be influenced by 1,25(OH)2D3 [6–11]. More that 80 years
prior to the demonstration of the role of vitamin D in immune
function, cod liver oil or exposure to sun, both sources of vitamin D,
were used to treat tuberculosis (Reviewed in: [2,12]. Then in 1986,
Rook and co-workers showed that 1,25(OH)2D3 induced anti-
tuberculosis activity in cultured monocytes [13]. Additionally,
1,25(OH)2D3 has been found to affect monocyte chemotaxis [14]
and act as an adjuvant in the production of bacterial-specific
antibodies [15]. In 2006, a seminal paper waspublished by Liu et. al.
[16] in which they demonstrated that toll-like receptor (TLR)
activation of monocytes induced 25-hydroxyvitamin D-1a-hydrox-
ylase (1a -hydroxylase). 1-hydroxylase converts 25-hydroxyvitamin
D3 (25(OH)D3) to the active 1,25(OH)2D3. 1,25(OH)2D3 induced
the antimicrobial peptide cathelicidin and inhibited the growth of
Mycobacterium tuberculosis. Furthermore, they showedthat cathelicidin
induction was compromised when using serum from donors with
low 25(OH)D3. This suggested that maintaining vitamin D status
above that needed for normal calcium homeostasis was required for
optimal immune responses via this newly highlighted intracrine
pathway.
Associations between serum 25(OH)D3 concentrations and
optimal immune function is now a subject of significant scrutiny.
Levels of serum 25(OH)D3, sufficient for full functionality of the
immune system are thought to be higher than levels needed for
proper skeletal formation [17,18]. Using samples collected as part
of the National Health and Nutrition Examination Survey,
researcher determined the levels of 25(OH)D3 in various
populations [19]. Their data indicated that in humans only 20–
25% of the population has 25(OH)D3 levels considered immuno-
logically sufficient (.30 ng/ml) [17,19]. There is an inverse
correlation between serum 25(OH)D3 levels and the risk for upper
respiratory tract infections [20], tuberculosis [21], and multiple
sclerosis [22]. Dietary supplementation of vitamin D has been
shown to decrease the risk of relapse in multiple sclerosis patients
[23] and decreases the risk of influenza A infections [24]. Together
this information indicates an important role of vitamin D in the
clearance of infections and containment of inflammation by the
body’s immune cells.
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and the role of vitamin D in modulating the immune system’s
response to pathogens. First, it is known that intramammary
infections activate bovine macrophages found in the milk through
the TLR pathways resulting in the upregulation of the expression
of the 1a-hydroxylase gene. The expression of 1a-hydroxylase is
responsible for the conversion of 25(OH)D3 to active hormone
1,25(OH)2D3 [4]. The production of 1,25(OH)2D3 leads to
changes in gene expression in macrophages isolated from milk of
an infected gland [3]. Therefore, the intracrine pathway described
in humans [16] is active in the bovine mammary gland
macrophages during a bacterial infection, but fails to induce the
induction of cathelicidin [4]. A second important aspect of
studying the role of vitamin D in mammary gland infections, is
that milk is deficient in 25(OH)D3. The levels of 25(OH)D3 in milk
are only 0.3–0.6 ng/ml [25], thus immune cells are devoid of a
source of 25(OH)D3 after they enter the infected mammary gland.
The hypothesis tested in these experiments was that infusion of
25(OH)D3 into the mammary gland of a dairy cow infected with
Streptococcus uberis would reduce the severity of the infection.
Materials and Methods
Animals
Ten mid-lactation primiparous Holstein cows at the USDA
National Animal Disease Center were used for this study. The
National Animal Disease Center animal care and use committee
approved all animal-related procedures used in this study (Protocol
ARS-4001). Prior to the study, all cows were healthy and bacteria
were not detected in their milk prior to the study. Cows were feed
a standard ration, which included between 30,000 and 40,000 IU
of vitamin D per day. Cows were milked two times a day.
Infection and Treatment
Mammary gland infection was induced by infusion of
approximately 500 cfu of Streptococcus uberis strain 0140 (S. uberis;
a gift from Dr. Max Paape, USDA, Beltsville, MD) suspended in
10 mL of FBS into one quarter of all ten cows. Infected animals
were randomly divided into two treatment groups: the first group
received 100 ug of 25(OH)D3 in 10 ml of FBS in the infected
quarter at the completion of each milking, starting at the time of
infection and continuing throughout the experiment. The second
group received 10 ml of FBS only in the infected quarter at the
completion of each milking. Antibiotics were not used during the
study.
Collection of milk, blood and temperature data
Milk samples were aseptically collected from infected quarters at
each milking (twice daily) throughout the study. Milk was used for
determination of bacterial counts, somatic cell counts, determina-
tion of bovine serum albumin (BSA) levels, and 25(OH)D3 levels.
Milk was serially diluted in sterile phosphate-buffered saline and
spread on blood agar plates, then incubated for 24 h at 37uC.
Following incubation, plates were examined for bacterial growth
and colonies enumerated.
Milk somatic cell counts were determined by sampling milk,
adding a preservative, and counting at a Dairy Herd Information
Association (DHIA) (Dubuque, IA) approved facility. Bovine
serum albumin levels in the milk were measured using a
commercial ELISA quantitation kit (Bethyl Laboratories, Mon-
tgomery, TX). The kit was used according to manufacturer’s
protocol and protein concentrations determined using the
included standards.
Blood samples (10 ml) were taken by venipuncture of the
jugular vein once a day. Serum was obtained by centrifugation.
The levels of 25(OH)D3 in the serum were determined by a
radioimmunoassay [26].
Rectal temperatures were obtained twice a day, at the time of
milking.
Statistical analysis
Data were analyzed as a completely randomized design (JMP
version 7 SAS Institute Inc., Cary, NC). Cow served as the
experimental unit in the analysis of all data. Effects of treatments
on variables (i.e. bacterial counts, rectal temperatures, somatic cell
counts, serum albumin, feed intake, milk production) were
analyzed with repeated-measures ANOVA. Bacterial and somatic
cell counts were log10 transformed prior to analysis. The model
included the fixed effects of treatment, time, and treatment x time
interaction. Post hoc tests were applied when treatment, time, or
treatment x time effects were detected. The values presented for all
variables are the means and standard errors of the mean.
Results
All ten animals were successfully infected with S. uberis.
Establishment of infection was indicated by at least one time
point having a bacterial count of greater than 1000 cfu/ml (data
not shown). Figure 1 shows the mean bacterial counts of the
25(OH)D3 treated group and the control group. There was a
significant effect (P,0.05) of the 25(OH)D3 treatment (figure 1). In
addition, there were significant reductions (P,0.05) in milk
bacterial counts at the fourth, sixth, and ninth milkings in the
25(OH)D3 treatment group compared to the control group.
Additional indicators of a mammary gland infection were
monitored, including rectal temperatures, somatic cell counts, and
BSA in the milk. Rectal temperatures showed a 25(OH)D3
treatment effect with a P =0.065 and are plotted in figure 2.
There was a continuation of the trend that the 25(OH)D3 treated
group had a better clinical outcome, in that somatic cell counts
were lower in the 25(OH)D3 treated group (figure 3). Acute
bacterial infections are known to increase mammary vascular
permeability, an indicator of this change is increased BSA levels in
milk [27]. Milk from the morning milking was tested by ELISA for
BSA (figure 4). Day 3 levels of BSA were higher in the control
animals compared to the 25(OH)D3 treated animals (P =0.07).
Mastitis causes reduction of both feed intake and milk
productions, and the level of reduction correlates with the severity
of the infection. The pre-infected feed intake and milk production
was calculated as the average of the values from the four days prior
to the infection. There was a trend for the 25(OH)D3 treated
animals to have higher average feed intake (figure 5). There was a
significant (P ,0.05) time x treatment effect, as the 25(OH)D3
treated animals milk production decline due to the infection
occurred later in the infection compared to control cows (figure 6).
Table 1 shows the blood serum levels of 25(OH)D3 in the
control animals compared to the 25(OH)D3 treated animals. This
data demonstrates that the dose of 100 ug 25(OH)D3 twice daily
did not affect (P.0.10) blood serum 25(OH)D3 levels.
Discussion
In a recent review it was stated that ‘‘Data from several models
of infection have so far not supported a role of vitamin D in
affecting the course of disease’’ [28]. These authors’ conclusions
are based on 1) the lack of in vivo evidence for an effect of vitamin
D status on the course of disease and 2) the findings that 1,
Treatment of an Infection with 25-Hydroxyvitamin D3
PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e2547925(OH)2D3 inhibits T helper cell functions that are important in
many infections and which we have characterized in vitro using a
cow model [29]. The data presented in this study demonstrate that
in vivo administration of 25(OH)D3, used as a treatment, reduces
the severity of an intramammary infection. The effectiveness of
25(OH)D3 may be due to many factors, including a predominant
Figure 1. Bacterial Counts in Control and 25(OH)D3 Treated Animals. Ten dairy cattle were infused with approximately 500 cfu of S. uberis in
one quarter of their mammary gland. Five cows were immediately treated with 100 ug of 25(OH)D3 in FBS and the remain five cows were treated
with FBS alone. Cows were subsequently treated after each milking (twice daily) with 25(OH)D3 or FBS for 10 milkings (5 days). Milk sample were
isolated from each cow and serially diluted and plated on blood agar plates. Average bacterial counts were determined for 25(OH)D3 treated (u) and
control animals(n). Time points with statistically significant differences are indicated with (*).
doi:10.1371/journal.pone.0025479.g001
Figure 2. Rectal Temperature in Control and 25(OH)D3 Treated Animals. Rectal temperature were taken twice daily, at each milking, and the
average was determined for 25(OH)D3 treated (u) and control animals(n).
doi:10.1371/journal.pone.0025479.g002
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normally has low 25(OH)D3 levels. Monocytes/macrophages play
a critical role in the immune response to mastitis [30] and
intracrine produced 1,25(OH)2D3 effects many aspects of the
innate immune system [31] and specifically macrophages
antimicrobial mechanisms [2,5]. Our ability to demonstrate in
vivo efficacy of 25(OH)D3 on a bacterial infection (figure 1) may
be due to the fact that the milk compartment of the mammary
gland is relatively devoid of 25(OH)D3, even though systemic
vitamin D status is excellent (table 1). Concentrations of 25(OH)D3
in milk are only 0.3–0.6 ng/ml compared to 35 ng/ml in serum
considered necessary for full immune function [17,18,25]. It may
Figure 3. Somatic Cell Counts in Control and 25(OH)D3 Treated Animals. Milk samples for somatic cells counts (SCC) were taken at each
milking and sent to a DHIA facility for counting. The average SCC were determined for 25(OH)D3 treated (u) and control animals(n).
doi:10.1371/journal.pone.0025479.g003
Figure 4. Bovine Serum Albumin in Milk of Control and 25(OH)D3 Treated Animals. Milk samples were tested for BSA levels at each time
point and the average was determined for 25(OH)D3 treated (u) and control animals(n).
doi:10.1371/journal.pone.0025479.g004
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PLoS ONE | www.plosone.org 4 October 2011 | Volume 6 | Issue 10 | e25479Figure 5. Feed Intake in Control and 25(OH)D3 Treated Animals. Daily feed intake was determined for each cow. Data are expressed as a
percentage of the pre-infections (the average of the 4 days feed intake prior to infection). Each the average was determined for 25(OH)D3 treated (u)
and control animals(n).
doi:10.1371/journal.pone.0025479.g005
Figure 6. Milk Production in Control and 25(OH)D3 Treated Animals. Daily milk production was determined for each cow. Data are
expressed as a percentage of the pre-infections (the average of the 4 days milk production prior to infection). Each the average was determined for
25(OH)D3 treated (u) and control animals(n). Repeated measures analysis showed a significant treatment x time effect.
doi:10.1371/journal.pone.0025479.g006
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circulating 25(OH)D3, will only be effective for infections in
anatomical locations with low concentrations of 25(OH)D3, such
as the mammary gland, and possilby the lung, and upper
respiratory tract. It is thus important to note that the data
presented here did not directly address the broader issue of
‘‘systemic vitamin D status’’ on the course of disease. However,
these data clearly demonstrate that increasing 25(OH)D3 concen-
trations in a tissue with low 25(OH)D3 concentrations can
positively influence the early course of the disease.
In this study, the treatment of an intramammary infection with
25(OH)D3 reduced bacterial counts (figure 1), decreased the
severity of the disease (figures 2, 3, 4, 5), and delayed loss of milk
production (figure 6). Based on human studies [16] these results
would depend on the ability of activated monocytes/macrophages
to produce 1,25(OH)2D3 from 25(OH)D3 and to induce
antibacterial peptides such as cathelicidin. Bovine monocytes/
macrophages produces 1,25(OH)2D3 from 25(OH)D3 both in vitro
[4] and in vivo [3] following bacterial activation. Unlike human
monocytes, bovine moncytes stimulated with 1,25(OH)2D3 does
not lead to the induction of antibacterial cathelicidins in the cattle
[4]. To date, only a few genes in bovine have been identified as
responsive to 1,25(OH)2D3 , namely, nitric oxide synthetase , the
chemokine RANTES, vitamin D receptor, S100 calcium binding
protein A12 (S100A12), and 24-hydroxylase [3,4,29]. Presumably
other immune mediators are involved in the vitamin D immune
pathway and experiments to determine them are ongoing. We do
not know whether the lower bacterial counts in the 25(OH)D3
treated animal are the result of enhanced nitric oxide killing,
specific leukocyte recruitment, and/or production of a yet
unidentified antibacterial peptide.
Administration of 25(OH)D3 is known to affect the innate
immune system [2,17,31]. In the case of humans 1,25(OH)2D3
treatment can cause increased expression of cathelicidins or
defensins [32], and in the case of cattle 1,25(OH)2D3 treatment
can cause increased expression in nitric oxide and RANTES [4].
Since the first significant affect of 25(OH)D3 treatment was seen at
48 hours (fourth milking) of infection, it is likely that the affect of
1,25(OH)2D3 treatment is on the innate immune system.
However, we have recently shown that the bovine adaptive
immune system is also sensitive to 25(OH)D3 treatment [29]. In
those experiments, cattle were immunized with an antigen several
weeks prior to the experiment. We showed that antigen-stimulated
PBMC from those immunized cattle, when treated with antigen
and 25(OH)D3 suppressed IFN-c and IL-17F in T cells. The role
of T cells in bovine mastitis is not well defined, however,
reinfection of animals treated and not treated with 25(OH)D3
would begin to assess the role of the affect of vitamin D on the
adaptive immune system during an infection.
At the end of this experiment all animals were treated with
antibiotics to eliminate the S. uberis infections indicating that
25(OH)D3 treatment alone was not an effective in eliminating the
infection. However, the reduction in the number of bacteria and
severity of disease shown in this study suggests that 25(OH)D3 maybe
effective in combination with antibiotics. This combined-treatment
approach may allow for reductions in antibiotic use and diminish
concerns about antibiotic residues in the dairy products and
development of antibiotic resistance in food animals. Although not
evaluated in the present study a combined antibiotic and vitamin D
therapy may provide an effective treatment strategy for chronic
infections that are not effectively treated by antibiotics alone.
In conclusion we demonstrated for the first time a positive in
vivo effect of intramammary administration of 25(OH)D3 on the
course of a bacterial infection in the mammary gland. This finding
suggested a significant non-antibiotic complimentary role for
25(OH)D3 in the treatment of infections in compartments
naturally low in 25(OH)D3 such as the mammary gland and by
extension, a potentially useful treatment of lung/respiratory tract
infections via aerosol administration. These experiments were
designed to focus on the early innate immune response to
experimental intramammary infection and do not address to affect
of 25(OH)D3 on adaptive immunity to bacterial infections. Further
studies will be needed to address these important questions.
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